pharmazz

Alzheimer's Disease

  • Gulati, A., Hornick, M. G., Briyal, S., and Lavhale, M. S. (2018) A novel neuroregenerative approach using ET(B) receptor agonist, IRL-1620, to treat CNS disorders. Physiol Res 67, S95-S113
    Read more
  • Briyal, S., Nguyen, C., Leonard, M., and Gulati, A. (2015) Stimulation of endothelin B receptors by IRL-1620 decreases the progression of Alzheimer's disease. Neuroscience 301, 1-11
    Read more
  • Oesterling, B. M., Gulati, A., and Joshi, M. D. (2014) Nanocarrier-based approaches for treatment and detection of Alzheimer's disease. J Nanosci Nanotechnol 14, 137-156
    Read more
  • Briyal, S., Shepard, C., and Gulati, A. (2014) Endothelin receptor type B agonist, IRL-1620, prevents beta amyloid (Aβ) induced oxidative stress and cognitive impairment in normal and diabetic rats. Pharmacol Biochem Behav 120, 65-72
    Read more
  • Briyal, S., Philip, T., and Gulati, A. (2011) Endothelin-A receptor antagonists prevent amyloid-beta-induced increase in ETA receptor expression, oxidative stress, and cognitive impairment. J Alzheimers Dis 23, 491-503
    Read more